Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Meridian Bioscience Downgraded by Canaccord to Sell Rating

Meridian Bioscience Downgraded by Canaccord to Sell Rating

Apr 03, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Following Meridian Bioscience's preliminary fiscal second quarter revenues that fell short of the analysts' average estimate, investment bank Canaccord Genuity today downgraded the company's shares to a Sell rating from a previous Hold rating.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In PCR

  1. BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

  2. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  3. Qiagen Reports Preliminary Q2 Revenue Growth of 18 to 19 Percent

  4. FDA Grants EUAs for Enzo Life Sciences, Access Bio, Gene By Gene Coronavirus Tests

  5. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.